IDEXX Laboratories, Inc. $IDXX Stock: Legacy Wealth Asset Management LLC Trims Position

Key Points

• Legacy Wealth Asset Management cut its IDEXX Laboratories position by 76.7% in the third quarter, selling 2,503 shares and retaining 762 shares worth about $398,000. Institutional investors collectively own 87.84% of the company.
• IDEXX reported quarterly earnings of $4.27 per share, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company issued fiscal 2026 EPS guidance of $14.69 to $14.94.
• Analyst sentiment remains positive but mixed, with six Buy ratings and four Holds producing a “Moderate Buy” consensus and an average price target of $747, well above the stock’s recent $518 price.

Legacy Wealth Asset Management LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 76.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 762 shares of the company's stock after selling 2,503 shares during the period. Legacy Wealth Asset Management LLC's holdings in IDEXX Laboratories were worth $398,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. GAMMA Investing LLC lifted its holdings in shares of IDEXX Laboratories by 1.8% in the 3rd quarter. GAMMA Investing LLC now owns 3,357 shares of the company's stock valued at $1,753,000 after buying an additional 60 shares during the period. Bell Asset Management Ltd acquired a new position in IDEXX Laboratories during the third quarter worth $2,735,000. Invariant Investment Management purchased a new stake in IDEXX Laboratories during the third quarter worth $590,000. Farther Finance Advisors LLC grew its holdings in IDEXX Laboratories by 44.1% in the third quarter. Farther Finance Advisors LLC now owns 5,577 shares of the company's stock valued at $2,912,000 after purchasing an additional 1,706 shares during the last quarter. Finally, CoreCap Advisors LLC boosted its position in shares of IDEXX Laboratories by 53.0% in the 3rd quarter. CoreCap Advisors LLC now owns 127 shares of the company's stock worth $66,000 after buying an additional 44 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 0.9%

NASDAQ IDXX opened at $518.00 on Friday. The stock has a market cap of $40.81 billion, a P/E ratio of 36.43, a PEG ratio of 2.74 and a beta of 1.55. The company's fifty day simple moving average is $538.96 and its 200-day simple moving average is $553.07. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. During the same period in the prior year, the company posted $3.50 EPS. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company's stock, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.79% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Citigroup raised their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. UBS Group raised their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday. Barclays decreased their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $747.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX's companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.